Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

RPS6KA3 gRNA (BRDN0001144943) Citations (1)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437.
PubMed Journal

Articles Citing RPS6KA3 gRNA (BRDN0001144943)

Articles
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y, Miura O. Cancers (Basel). 2019 Nov 20;11(12). pii: cancers11121827. doi: 10.3390/cancers11121827. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.